# TherapeuticsMD, Inc.

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/en/companies/TherapeuticsMD, Inc.).

## Overview

TherapeuticsMD, Inc. is a U.S.-based pharmaceutical royalty company focused on women’s healthcare products. Through licensing arrangements, it receives royalties tied to branded prescription products including IMVEXXY, BIJUVA, ANNOVERA, and prenatal vitamin brands sold in the United States and its territories.

## Products & services

• Royalties from IMVEXXY vaginal inserts
• Royalties from BIJUVA hormone therapy capsules
• Royalties from ANNOVERA contraceptive ring
• Royalties from BocaGreenMD and vitaMedMD prenatal vitamins
• License and royalty rights for women’s healthcare products

- **Prescription women’s health royalties** (85%) — Royalty streams tied to licensed prescription products for menopause, contraception, and prenatal care.
- **Prenatal vitamin brands** (15%) — Royalties from prescription prenatal vitamin products sold under BocaGreenMD and vitaMedMD.

- Royalties from IMVEXXY vaginal inserts
- Royalties from BIJUVA hormone therapy capsules
- Royalties from ANNOVERA contraceptive ring
- Royalties from BocaGreenMD and vitaMedMD prenatal vitamins
- License and royalty rights for women’s healthcare products

## Customers

TherapeuticsMD’s direct commercial counterparties are pharmaceutical licensees and distributors that market its licensed products in the United States and its territories. End demand comes from women treated for menopause-related symptoms, contraception needs, and prenatal supplementation, but the company itself monetizes that demand through royalty agreements rather than direct sales. Its revenue therefore depends on the commercial execution of its licensees and the underlying prescription volumes of the branded products.

- **Licensee pharmaceutical partners** (primary) — Mayne Pharma and other commercial partners pay royalties and market the licensed products.
- **Menopause therapy patients** (primary) — Patients using IMVEXXY and BIJUVA for menopause-related symptoms drive royalty-bearing sales.
- **Contraception patients** (secondary) — Users of ANNOVERA generate prescription volume for the licensed contraceptive product.
- **Prenatal supplement users** (secondary) — Patients and prescribers using BocaGreenMD and vitaMedMD prenatal vitamins support royalty income.

- Pharmaceutical licensees that commercialize the branded products
- Women’s health patients using menopause and contraception therapies
- Prescribers in OB/GYN and related women’s health specialties
- Pharmacy and distribution channels supporting prescription fill volumes
- Prenatal care customers purchasing branded vitamin products

## Geography

The company’s royalty portfolio is concentrated in the United States and its possessions and territories, where the licensed products are commercialized. That geographic concentration makes revenue dependent on U.S. prescription demand, payer access, and the execution of its U.S. licensee. The business has limited operating geography because it no longer runs a direct commercial or R&D platform.

- **United States and territories** (100%) — Licensed products are commercialized in the U.S. and its possessions and territories.

- Revenue is concentrated in the United States and its territories
- Licensed products are commercialized under U.S. rights only
- Geographic exposure is tied to U.S. prescription and payer dynamics
- No meaningful direct international operating footprint is disclosed
- Royalty model reduces physical manufacturing geography exposure

## Strategy

TherapeuticsMD’s strategy is to monetize its women’s healthcare portfolio through royalty and license agreements rather than direct commercialization. The business depends on protecting its contractual rights, collecting royalties from licensees, and preserving the value of its branded product portfolio. Because revenue is driven by partner sales, the company’s strategic focus is on license enforcement, dispute resolution, and maintaining the economic terms of its agreements.

- **Maximize royalty collection from licensed products** (short-term) — Royalty income is the company’s core operating model and main source of revenue.
- **Defend and enforce contractual economics** (short-term) — Disputes over rebates, returns, and working capital can change cash receipts and reported revenue.
- **Maintain value of licensed women’s health brands** (medium-term) — The royalty stream depends on continued market demand for the underlying products.

- Monetize women’s health brands through royalty agreements
- Depend on licensee commercialization rather than direct sales
- Protect contractual rights and royalty calculations
- Preserve value of IMVEXXY, BIJUVA, ANNOVERA and prenatal brands
- Manage disputes and working-capital true-ups with partners

## Risks

TherapeuticsMD faces concentrated counterparty risk because most of its economics depend on a small number of license agreements, especially with Mayne Pharma. The company also carries litigation, royalty-calculation, and going-concern risk, since lower-than-expected partner sales or adverse dispute outcomes could reduce cash inflows and strain liquidity. As a royalty business, it is also exposed to prescription demand trends, payer access, and execution risk at the licensee level rather than its own commercial operations.

- **Mayne Pharma contractual disputes** [high] — Allowance calculations, returns, rebates, and working-capital true-ups can alter revenue and cash collections.
- **Going-concern and liquidity pressure** [critical] — The company disclosed substantial doubt about its ability to continue as a going concern if cash inflows disappoint.
- **Concentration in a few licensed products** [high] — A small portfolio means sales declines in one product can materially affect total royalties.
- **Licensee execution risk** [medium] — TherapeuticsMD relies on third parties for commercialization, supply chain, and market access.

- Revenue depends on a small number of license agreements
- Mayne Pharma disputes could reduce royalties or cash receipts
- Lower partner sales would directly reduce royalty income
- Going-concern risk if cash inflows and financing are insufficient
- Prescription and payer dynamics affect underlying product demand

## Accounting

The most important accounting issue is revenue recognition for license and royalty arrangements, including estimates tied to sales-based royalties, rebates, returns, and minimum annual royalty provisions. Investors should also watch receivables from Mayne Pharma, because working-capital settlements and disputed allowances can affect both current and long-term balances. As a royalty company with discontinued operations and asset write-offs, judgment around impairment, collectability, and contingent claims can materially affect reported results.

- **Royalty revenue recognition** — Affects reported license revenue and receivables
- **Allowance estimates for rebates, returns, and distributor fees** — Affects net revenue and working-capital settlements
- **Royalty receivable collectability** — Affects balance sheet valuation and liquidity assessment
- **Impairment and write-offs** — Affects operating expenses and asset values

- Royalty revenue depends on partner sales and contract terms
- Allowance estimates for rebates and returns affect revenue timing
- Royalty receivables from Mayne Pharma affect collectability risk
- Impairment and write-offs can affect reported operating results
- Discontinued operations can distort comparability across periods

---

*Last updated: 2026-04-29T05:03:38.987083+00:00*